{"id":191540,"date":"2024-06-21T00:27:20","date_gmt":"2024-06-21T05:27:20","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2024\/06\/subcutaneous-versus-iv-nivolumab-for-kidney-cancer"},"modified":"2024-06-21T00:27:20","modified_gmt":"2024-06-21T05:27:20","slug":"subcutaneous-versus-iv-nivolumab-for-kidney-cancer","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2024\/06\/subcutaneous-versus-iv-nivolumab-for-kidney-cancer","title":{"rendered":"Subcutaneous Versus IV Nivolumab for Kidney Cancer"},"content":{"rendered":"<p><\/p>\n<p><iframe style=\"display: block; margin: 0 auto; width: 100%; aspect-ratio: 4\/3; object-fit: contain;\" src=\"https:\/\/www.youtube.com\/embed\/adLrytajoxc?feature=oembed\" frameborder=\"0\" allow=\"accelerometer; autoplay; encrypted-media; gyroscope;\n   picture-in-picture\" allowfullscreen><\/iframe><\/p>\n<p>For people with advanced <a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"22e69599-aaa8-42ed-96e6-50892feb7761\" href=\"https:\/\/www.cancer.gov\/types\/kidney\">kidney cancer<\/a>, an injectable form of <a data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"0ebd801b-ec5f-45e3-97c4-f40a5b0cf2ca\" href=\"https:\/\/www.cancer.gov\/about-cancer\/treatment\/drugs\/nivolumab\">nivolumab (Opdivo)<\/a> is a suitable alternative to the original intravenous form, early results from a clinical trial have shown. Experts say the injectable form makes the treatment quicker and easier for patients to receive.<\/p>\n<p>As a result, \u201cpatients\u2019 treatment experience will be significantly improved,\u201d said the trial\u2019s leader, Saby George, M.D., of Roswell Park Comprehensive Cancer Center in Buffalo, NY.<\/p>\n<p>The clinical trial involved nearly 500 people with advanced or metastatic kidney cancer. All participants were randomly assigned to receive a new form of nivolumab that is given as injection under the skin (subcutaneous) or the original form, which is given through a vein (an intravenous infusion, or IV).<\/p>\n","protected":false},"excerpt":{"rendered":"<p>For people with advanced kidney cancer, an injectable form of nivolumab (Opdivo) is a suitable alternative to the original intravenous form, early results from a clinical trial have shown. Experts say the injectable form makes the treatment quicker and easier for patients to receive. As a result, \u201cpatients\u2019 treatment experience will be significantly improved,\u201d said [\u2026]<\/p>\n","protected":false},"author":662,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"class_list":["post-191540","post","type-post","status-publish","format-standard","hentry","category-biotech-medical"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/191540","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/662"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=191540"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/191540\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=191540"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=191540"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=191540"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}